Phase III trial to compare adjuvant chemotherapy with capecitabine and cisplatin versus concurrent chemoradiotherapy in gastric cancer: Final report of the adjuvant chemoradiotherapy in stomach tumors trial, including survival and subset analyses

Journal of Clinical Oncology

Volumn 33, Issue 28, 2015, Pages 3130-3136

  Park, Se Hoon ^a   Sohn, Tae Sung ^a   Lee, Jeeyun ^a   Lim, Do Hoon ^a   Hong, Min Eui ^a   Kim, Kyoung Mee ^a   Sohn, Insuk ^a   Jung, Sin Ho ^a   Choi, Min Gew ^a   Lee, Jun Ho ^a   Bae, Jae Moon ^a   Kim, Sung ^a   Kim, Seung Tae ^a   Park, Joon Oh ^a   Park, Young Suk ^a   Lim, Ho Yeong ^a   Kang, Won Ki ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CAPECITABINE; CISPLATIN; ANTINEOPLASTIC AGENT;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CHEMORADIOTHERAPY; CLINICAL PROTOCOL; COMPARATIVE STUDY; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DISEASE SEVERITY; FEMALE; FOLLOW UP; GASTRECTOMY; HAZARD RATIO; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STATISTICAL ANALYSIS; STOMACH CANCER; SUBSET ANALYSIS; TISSUE MICROARRAY; TREATMENT OUTCOME; ADJUVANT CHEMORADIOTHERAPY; ADJUVANT CHEMOTHERAPY; ADVERSE EFFECTS; CANCER STAGING; CLINICAL TRIAL; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; SOUTH KOREA; STOMACH NEOPLASMS; TIME FACTOR; YOUNG ADULT;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAPECITABINE; CHEMORADIOTHERAPY, ADJUVANT; CHEMOTHERAPY, ADJUVANT; CISPLATIN; DISEASE-FREE SURVIVAL; FEMALE; GASTRECTOMY; HUMANS; KAPLAN-MEIER ESTIMATE; LYMPH NODE EXCISION; MALE; MIDDLE AGED; NEOPLASM STAGING; PROPORTIONAL HAZARDS MODELS; REPUBLIC OF KOREA; STOMACH NEOPLASMS; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84939212026     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2014.58.3930     Document Type: Article

References (17)

1. Macdonald JS, Smalley SR, Benedetti J, et al: Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 345: 725-730, 2001
2. Smalley SR, Benedetti JK, Haller DG, et al: Updated analysis of SWOG-directed intergroup study 0116: A phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection. J Clin Oncol 30: 2327-2333, 2012
3. Huang YY, Yang Q, Zhou SW, et al: Postoperative chemoradiotherapy versus postoperative chemotherapy for completely resected gastric cancer with D2 Lymphadenectomy: A meta-Analysis. PLoS One 8: E68939, 2013
4. Sano T, Sasako M, Yamamoto S, et al: Gastric cancer surgery: Morbidity and mortality results from a prospective randomized controlled trial comparing D2 and extended para-Aortic lymphadenectomy-Japan Clinical Oncology Group study 9501. J Clin Oncol 22: 2767-2773, 2004
5. Hartgrink HH, van de Velde CJ, Putter H, et al: Extended lymph node dissection for gastric cancer: Who may benefit? Final results of the randomized Dutch Gastric Cancer Group Trial. J Clin Oncol 22: 2069-2077, 2004
6. Sakuramoto S, Sasako M, Yamaguchi T, et al: Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med 357: 1810-1820, 2007
7. Bang YJ, Kim YW, Yang HK, et al: Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): A phase 3 open-label, randomised controlled trial. Lancet 379: 315-321, 2012
8. Lee J, Lim do H, Kim S, et al: Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: The ARTIST trial. J Clin Oncol 30: 268-273, 2012
9. Song HJ, Srivastava A, Lee J, et al: Host inflammatory response predicts survival of patients with Epstein-Barr virus-Associated gastric carcinoma. Gastroenterology 139: 84-92.e2, 2010
10. Cunningham D, Allum WH, Stenning SP, et al: Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 355: 11-20, 2006
11. Bickenbach K, Strong VE: Comparisons of gastric cancer treatments: East vs. west. J Gastric Cancer 12: 55-62, 2012
12. Cuschieri A, Weeden S, Fielding J, et al: Patient survival after D1 and D2 resections for gastric cancer: Long-Term results of the MRC randomized surgical trial-Surgical Co-operative Group. Br J Cancer 79: 1522-1530, 1999
13. Songun I, Putter H, Kranenbarg EM, et al: Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial. Lancet Oncol 11: 439-449, 2010
14. Sasako M, Sakuramoto S, Katai H, et al: Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. J Clin Oncol 29: 4387-4393, 2011
15. Adachi Y, Yasuda K, Inomata M, et al: Pathology and prognosis of gastric carcinoma: Well versus poorly differentiated type. Cancer 89: 1418-1424, 2000
16. Brooks GA, Enzinger PC, Fuchs CS: Adjuvant therapy for gastric cancer: Revisiting the past to clarify the future. J Clin Oncol 30: 2297-2299, 2012
17. Bang YJ, Van Cutsem E, Feyereislova A, et al: Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): A phase 3, open-label, randomized controlled trial. Lancet 376: 687-697, 2010